These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34623078)

  • 1. Home Induction of Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
    Kelly JC; Raghuraman N; Stout MJ; Russell S; Perez M; Nazeer S; El Helou N; Zhang F; Carter E
    Obstet Gynecol; 2021 Oct; 138(4):655-659. PubMed ID: 34623078
    [No Abstract]   [Full Text] [Related]  

  • 2. Buprenorphine medication-assisted treatment during pregnancy: An exploratory factor analysis associated with adherence.
    Coker JL; Catlin D; Ray-Griffith S; Knight B; Stowe ZN
    Drug Alcohol Depend; 2018 Nov; 192():146-149. PubMed ID: 30253377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid Use Disorder and Pregnancy.
    O'Donnell FT; Jackson DL
    Mo Med; 2017; 114(3):181-186. PubMed ID: 30228577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Dose Buprenorphine Initiation in the Management of Opioid Use Disorder in Pregnancy.
    Berry M; Kiefer MK; Hinely KA; Bowden H; Jordan A; Vilensky M; Rood KM
    Obstet Gynecol; 2024 Jun; 143(6):815-818. PubMed ID: 38574367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
    Shulman M; Wai JM; Nunes EV
    CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment of opioid use disorder in pregnancy.
    Rodriguez CE; Klie KA
    Semin Perinatol; 2019 Apr; 43(3):141-148. PubMed ID: 30755340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?
    Stitzer ML
    Addiction; 2013 Feb; 108(2):249-50. PubMed ID: 23331877
    [No Abstract]   [Full Text] [Related]  

  • 8. Double trouble-pregnancy and antagonist treatment in opioid dependence; two contentious issues needing further consideration and research.
    Clark N; Verster A
    Addiction; 2013 Feb; 108(2):253-5. PubMed ID: 23331880
    [No Abstract]   [Full Text] [Related]  

  • 9. Observational study of buprenorphine treatment of opioid-dependent pregnant women in a family medicine residency: reports on maternal and infant outcomes.
    O'Connor A; Alto W; Musgrave K; Gibbons D; Llanto L; Holden S; Karnes J
    J Am Board Fam Med; 2011; 24(2):194-201. PubMed ID: 21383220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of outcome after short-term stabilization with buprenorphine.
    Hillhouse M; Canamar CP; Ling W
    J Subst Abuse Treat; 2013 Mar; 44(3):336-42. PubMed ID: 23021099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine Patch as a Bridge to Sublingual Treatment of Opioid Use Disorder in Pregnancy.
    Galati BM; Carter EB; Perez M; Russell S; Nazeer S; Raghuraman N; Kelly JC
    Obstet Gynecol; 2021 Apr; 137(4):713-716. PubMed ID: 33706342
    [No Abstract]   [Full Text] [Related]  

  • 12. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 13. Naltrexone in the treatment of opioid-dependent pregnant women: common ground.
    Jones HE; Chisolm MS; Jansson LM; Terplan M
    Addiction; 2013 Feb; 108(2):255-6. PubMed ID: 23331881
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative Management and Analgesia for Patients Taking Buprenorphine and Other Forms of Medication-Assisted Treatment for Substance Abuse Disorders.
    Scholzen E; Zeng AM; Schroeder KM
    Adv Anesth; 2019 Dec; 37():65-86. PubMed ID: 31677660
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why 24 State and Territorial Health Officials Support Buprenorphine Deregulation.
    Stancliff S; Greene D; Zucker HA
    Am J Public Health; 2019 Dec; 109(12):1678-1679. PubMed ID: 31693402
    [No Abstract]   [Full Text] [Related]  

  • 18. Buprenorphine offers a way to rise from the ashes of addiction.
    Newcomb A
    J Fam Pract; 2021 Sep; 70(7):317. PubMed ID: 34818160
    [No Abstract]   [Full Text] [Related]  

  • 19. Educating Nurses on the Use of the Clinical Opiate Withdrawal Scale to Improve Care of Adult Patients Undergoing Buprenorphine Induction.
    J Addict Nurs; 2020; 31(4):E38-E39. PubMed ID: 33264209
    [No Abstract]   [Full Text] [Related]  

  • 20. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.
    Northrup TF; Stotts AL; Green C; Potter JS; Marino EN; Walker R; Weiss RD; Trivedi M
    Addict Behav; 2015 Feb; 41():20-8. PubMed ID: 25282598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.